Anbio Biotechnology Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	6.92	8.19	6.71	23.54	4.43
Revenue Growth (YoY)	-27.17%	21.95%	-71.49%	431.67%	-
Cost of Revenue	0.71	2.3	3.35	10.98	1.89
Gross Profit	6.21	5.89	3.36	12.56	2.54
Selling, General & Admin	3.99	3.44	1.27	2.17	0.09
Research & Development	0.46	0.45	0.13	0.2	-
Operating Expenses	4.44	3.89	1.4	2.37	0.09
Operating Income	1.76	2	1.96	10.2	2.46
Interest Expense	-	-	-	-0.01	-
Interest & Investment Income	0.34	0.34	0.17	0.04	-
Currency Exchange Gain (Loss)	0.62	0.02	0.12	-0.26	-0
Other Non Operating Income (Expenses)	0.02	0.02	0.01	0.04	0.08
Pretax Income	2.57	2.37	2.25	10.01	2.54
Net Income	2.57	2.37	2.25	10.01	2.54
Net Income to Common	2.57	2.37	2.25	10.01	2.54
Net Income Growth	-40.55%	5.29%	-77.49%	294.79%	-
Shares Outstanding (Basic)	43	42	21	-	-
Shares Outstanding (Diluted)	43	42	21	-	-
Shares Change (YoY)	1.37%	97.30%	-	-	-
EPS (Basic)	0.06	0.06	0.11	-	-
EPS (Diluted)	0.06	0.06	0.11	-	-
EPS Growth	-41.35%	-46.63%	-	-	-
Gross Margin	89.70%	71.90%	50.07%	53.36%	57.40%
Operating Margin	25.50%	24.38%	29.22%	43.30%	55.46%
Profit Margin	37.20%	28.99%	33.58%	42.52%	57.26%
EBIT	1.76	2	1.96	10.2	2.46
EBIT Margin	25.50%	24.38%	29.22%	43.30%	55.46%
Revenue as Reported	6.92	8.19	6.71	23.54	4.43

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q